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ABSTRACT 
 
Background:  Perinatal asphyxia is caused by decreased oxygen delivery to neonates during the 
birthing process, and leads to significant neonatal morbidity and mortality. Acute kidney injury due 
to decreased oxygen delivery is a major adverse neonatal health outcome associated with perinatal 
asphyxia, and can lead to renal failure. Previous studies in low resource settings lacking induced 
hypothermia (the current standard of care in well-resourced countries) have used theophylline 
administered immediately following asphyxiation to prevent (or reduce) kidney injury. 
Purpose: To synthesize the current evidence on prophylactic theophylline in term infants with 
perinatal asphyxia for the prevention or treatment of acute kidney injury. 
Methods:  PubMed and EMBASE were searched from database inception through April 2016 using 
predefined criteria to identify RCTs comparing prophylactic theophylline to placebo in term infants 
following perinatal asphyxia examining incidence of acute kidney injury (AKI), serum creatinine 
levels (SCr), or glomerular filtration rates (GFR).  
Results:  Five RCTs met full inclusion criteria (N=356 infants) and were included in meta-analysis.  
The use of prophylactic theophylline was associated with a significant reduction in acute kidney 
injury compared with placebo (RR 0.36, 95% CI, 0.25 to 0.5; p <0.00001).  SCr levels were 
significantly lower in the theophylline group on days 3 and 5. Similarly, GFR levels were 
significantly increased on days 3 and 5 in the theophylline group compared to the control group. 
Conclusions: Prophylactic theophylline administration significantly reduces the incidence of acute 
kidney injury in asphyxiated term neonates and should be considered for routine use in low-resource 
settings lacking access to therapeutic hypothermia. Future research should examine theophylline in 
conjunction with therapeutic hypothermia, optimal dosing, and safety.  
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INTRODUCTION  
Perinatal asphyxia is a relatively common condition affecting newborns and can lead to 
significant morbidity and mortality. It is caused by reduced oxygenation due to decreased oxygen 
delivery during the birthing period. Perinatal asphyxia is a global problem, as an estimated 1.2 
million deaths worldwide can be attributed to birth asphyxia.1  As of 2006, the incidence of birth 
asphyxia was 4.3-8% in developed countries; however, the incidence was found to be much 
greater in developing countries at 23%.2,3 Asphyxiation leads to serious adverse perinatal health 
outcomes; the most common is hypoxic ischemic encephalopathy (HIE), with an estimated 
incidence of 50-72%.4  Birth asphyxia is the fifth most common cause of childhood death under 
5 years worldwide5  and also causes significant life-long morbidity, such as severe 
neurodevelopmental issues, cerebral palsy, and epilepsy.  These disabilities are estimated to 
cause a 42 billion disability adjusted life year (DALY) burden on society.5   
Perinatal asphyxia can be caused by placental abruption, vasa previa, uterine rupture, 
shoulder dystocia, cord prolapse, maternal cardiopulmonary arrest, and difficult or prolonged 
labor.6  The lack of neonatal oxygen from complications surrounding labor can result in serious 
long-term neurological sequelae such as brain damage resulting in cerebral palsy, seizures, as 
well as mental and physical disability.  HIE is a major complication that results from severe 
perinatal asphyxia.  As the signs and symptoms of HIE can be non-specific and similar to those 
that occur during other forms of infantile encephalopathy, there is no formal definition for the 
diagnosis of HIE.  However, one definition states that infants with HIE typically display low 
Apgar scores, low cord pH, neonatal seizures, and encephalopathy surrounding an asphyxiation 
event during labor and delivery.7  Neonatal encephalopathy is defined as a “heterogenous, 
clinically defined syndrome caused by a disturbance in neurological function in an infant born at 
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or beyond 35 weeks of gestation, manifested by a decreased level of consciousness or seizures, 
and often with difficulty initiating and maintaining respirations, as well as depression of tone and 
reflexes”.7 
Asphyxiation triggers a protective reflex in which blood is re-routed to the heart, brain, 
and adrenals to preserve vital organ functioning representing the first stage of the injury.  The 
second stage of injury occurs once the neonate has been delivered and stabilized.  Approximately 
six hours following birth, biochemical cascades induce oxidative stress, inflammation, and 
cytotoxicity.8  This second round of hypoxic-ischemic injury is thought to be the main driver of 
neurologic damage, so the current and only recommended treatment for reducing neurological 
outcomes related to HIE is induced hypothermia (also called therapeutic hypothermia) initiated 
within six hours of delivery.9  Between 2005 and 2011, six randomized control trials (RCTs) 
were conducted examining induced hypothermia for neonatal encephalopathy.10-15  Two out of 
the six studies used the induced hypothermia method of selective head cooling,10,13 while the 
other four studies used the whole body cooling method.11,12,14,15  Despite using the two different 
methods for cooling, all six studies included infants at least 35 weeks gestational age at birth 
cooled to a target temperature of 33.5-34.5ºC by at least 72 hours after birth followed by a slow 
rewarming period in which the temperature is only increased by 0.5ºC per hour.  Based on these 
clinical trials, the American Academy of Pediatrics (AAP) recommends candidates for induced 
hypothermia meet the inclusion criteria of being ≥ 36 weeks of age and ≤ 6 hours of age and 
having an Apgar score ≤ 5 at 10 minutes after birth, or having a continued need for resuscitation 
at 10 minutes after birth, or having a pH ˂ 7.0 or base deficit ≥ 16 mmol/L in umbilical cord 
blood or venous or arterial blood samples within an hour after birth, or having moderate to 
severe encephalopathy on clinical exam, or lastly having a moderately abnormal background for 
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20 minutes or seizure activity on an amplitude integrated electroencephalogram (aEEG) after one 
hour of age.16  While whole-body cooling seems to be effective in reducing neurologic sequelae, 
there is little data on the effects of this treatment for other organ system damage.  Despite the 
lack of specific treatment for other organ system injuries, damage to the heart, diaphragm, and 
kidneys frequently occurs.   
 The kidneys of neonates are particularly susceptible to damage during perinatal 
asphyxiation.  At birth, the neonatal kidneys only receive 2.5 to 4.0% of the cardiac output 
compared to 20 to 25% of the cardiac output received by adult kidneys.17  After birth, blood flow 
increases gradually over the next few weeks reaching almost to adult levels by 6 weeks.  As the 
newborn kidneys are not receiving the complete amount of blood flow until around 6 weeks, they 
are highly susceptible to any changes in perfusion.  The renin-angiotensin system along with 
prostaglandins also plays a role in helping the neonatal kidney adapt to life outside of the 
womb.17  However, this system is also fragile and easily affected periods of stress such as those 
caused by perinatal asphyxia.  During asphyxiation, blood flow to the kidneys is reduced, leading 
to renal hypoperfusion, acute kidney injury, and potentially renal failure.6,18  HIE specifically 
accounts for 30-40% of acute kidney injury in the newborn period.19,20  Mortality rates due to 
AKI from asphyxia is unknown. .4    
Challenges in the field of neonatology often arise due to lack of evidence from controlled 
trials enrolling neonates. Much of the research on neonatal treatments for various medical 
conditions have been studied in children first and then scaled down to infants.  Due to the paucity 
of published controlled trials in the literature, many existing protocols are based on expert 
opinion and recommendation.   
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A challenge in analyzing the amount of AKI and renal dysfunction due to perinatal 
asphyxia is that there are currently multiple different definitions for AKI used in the neonatal 
population. While in adults, there is a specific definition of AKI, there is no official 
internationally recognized definition for neonatal AKI, which has led to heterogeneity in the 
literature and in clinical practice.  In 2008, AKI was frequently arbitrarily defined in studies as 
an absolute serum creatinine (SCr) ≥ 1.5 mg/dL.17  Further studies such as the Risk, Injury, 
Failure, Loss of kidney function, and End-stage kidney disease (RIFLE) study and Acute Kidney 
Injury Network (AKIN) with their own definition of AKI.21,22  Following these studies, a 
definition of AKI was created was created that merged the definitions from the RIFLE and 
AKIN studies called the Kidney Disease Improving Outcomes (KDIGO) guidelines, which are 
based on the absolute rise of SCr from a previous nadir and are recommended for use in children 
up to 120 days.  According to the KDIGO guidelines, AKI is defined as having any of the 
following: increase in SCr by ≥ 0.3 mg/dL within 48 hours, or an increase in SCr to ≥ 1.5 times 
baseline (known or presumed to have occurred within the prior 7 days), or a urine volume ˂ 0.5 
ml/kg/h for 6 hours.23  The KDIGO guidelines also give staging criteria based on the severity of 
AKI to further help guide treatment.23  While the KDIGO guidelines offer a reasonable starting 
point for defining acute kidney injury, pediatric nephrologists and neonatologists at the 2013 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) workshop concluded 
that more research needed to be done regarding the specific degree of SCr rise, age of use, and 
how to deal with a rise of 0.2 to 0.3 (which is technically a 1.5 –fold increase, therefore meeting 
AKI criteria).17  The definitions of neonatal AKI that are most commonly used are a combination 
of rising SCr > 1.5 mg/dL with absolute cut-off values for the presence or absence of AKI, 
oliguria (1 ml/kg/h) and elevated blood urea nitrogen (BUN) > 39.9 mg/dL.4    
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The majority of AKI that occurs after HIE is pre-renal kidney injury.20  As such, 
supportive measures such as intravenous fluids and blood pressure control are mainstays of 
treatment for kidney injury.  While supportive treatments for AKI in the asphyxiated should be 
continued, additional interventions may prevent and improve outcomes associated with AKI in 
the asphyxiated neonate population.  Some literature suggests that adenosine receptor 
antagonists, such as theophylline and aminophylline, may be effective in preventing and 
improving AKI associated with neonatal asphyxia. These medications are becoming more 
commonly used in low resource settings outside of the United States that do not have access to 
induced hypothermia.  
Historically, theophylline has been implemented to successfully treat apnea of 
prematurity.  In this setting, theophylline acts at a respiratory stimulant by acting on the 
respiratory center of the central nervous system to reduce apnea frequency and improve 
ventilation via their ability to cause dilation of pulmonary vasculature.24  Theophylline has also 
been suggested to be beneficial for weaning premature infants from mechanical ventilation.25,26    
These drugs have been shown to stimulate the central nervous system (CNS) at all levels.24  One 
commonly reported side effect of toxic doses of aminophylline is CNS excitation leading to 
restlessness and seizures.27   The contraction, rate, and rhythm of the heart are also affected, and 
so can lead to tachycardia even at therapeutic doses.24  Methylxanthines also cause dilatation of 
systemic vascular systems, but constriction of cerebral vasculature.24  They cause stimulation of 
skeletal muscles, but relaxation of smooth muscles.24  In the gastrointestinal tract, 
methylxanthines can cause stimulation of gastric acid and fluid secretion.24  Lastly, 
methylxanthines cause increased renal blood flow and diuresis in the kidneys.  In the kidneys, 
adenosine receptor antagonists such as theophylline and aminophylline function by blocking 
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renal adenosine, which acts as a vasoconstrictor metabolite after hypoxemia.28  These adenosine 
receptor antagonists work independently from the inhibition of cyclic AMP phosphodiesterase.29  
Cytochrome P4501A2 is primarily responsible for the metabolism of theophylline in the adult 
kidney; however, this pathway is immature in the newborn kidney.30  Therefore, understanding 
the proper dosing of methylxanthines in the newborn infant is especially important for 
maximizing the therapeutic benefits and reducing harms. 
A few early studies in the 1980s examined the renal effects of different methylxanthines 
in newborn rabbits, whose renal maturation is highly similar to that of newborn infants.31  These 
studies mainly used doses of methylxanthines (theophylline and aminophylline) that were 
commonly being used in the clinical setting for apnea of prematurity.  One study comparing the 
effects of theophylline and caffeine demonstrated that the renal effects of methylxanthines were 
dose- and time-related after administration of 2.5 or 5 mg/kg theophylline.32  In a follow-up 
study comparing theophylline to enprofylline, a xanthine derivative with low adenosine blocking 
properties, researchers found that a 5 to 10 fold lower concentration of theophylline showed the 
same profile of renal changes as the lower dose.29  Specifically, these changes were an increase 
in filtration fraction and a slight increase in renal vascular resistance.29  Theophylline was also 
found to increase diuresis and sodium excretion in newborn rabbits.29  
Previous studies have also been performed to determine if prophylactic theophylline 
reduces kidney injury due to perinatal asphyxia.  In 2012, a systematic review and meta-analysis 
was done to look specifically at 4 RCTs involving 197 infants total.33  Compared to the placebo, 
prophylactic theophylline administration was associated with a significant reduction in severe 
renal dysfunction.33  This research reflects the use of prophylactic theophylline to reduce acute 
kidney injury, but does not examine the use of theophylline for treating existing acute kidney 
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injury.  In addition, this review does not include a newly published large RCT evaluating the 
efficacy of theophylline for preventing or improving renal dysfunction in term neonates with 
perinatal asphyxia.28  
In summary, prophylactic treatment with methylxanthines like theophylline or 
aminophylline may be a promising strategy for reducing adverse renal dysfunction associated 
with perinatal asphyxia. The purpose of this review is to provide an up-to-date synthesis of the 
literature evaluating the efficacy of theophylline or aminophylline for preventing or treating AKI 
in term neonates with perinatal asphyxia.     
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METHODS  
Questions 
The questions guiding our literature review were the following: 
Q1: What is the efficacy of theophylline/aminophylline for reducing the incidence and severity 
of acute kidney injury in infants with perinatal asphyxia?  
Q2: How does treatment affect measures of kidney function such as GFR, creatinine, and urinary 
β2 globulin?  
Q3: What are the harms associated with the use of theophylline/aminophylline in infants with 
perinatal asphyxia? 
 
Search Strategy 
          We searched PubMed and EMBASE from database inception through April 2017 for 
relevant published RCTs.  The search strategies for PubMed and EMBASE are included in 
Appendix Table 1, and include relevant terms for the population, interventions, and outcomes of 
interest.  Searches were limited to humans and English language, and search strategy was 
developed with the help of a health services librarian.   First, the specific study population was 
retrieved using the search terms ‘neonate’, ‘newborn’, and ‘infant’.  To help specify the 
condition of interest, we searched for the terms ‘asphyxiated’, ‘hypoxic ischemic 
encephalopathy’, and ‘HIE’.  To investigate treatments, the terms ‘theophylline’ and 
‘aminophylline’ were searched.  Lastly, to look at the outcomes of interest, the search terms 
‘acute kidney failure’ and more broadly using the search term “kidney”.  The Boolean search 
term ‘and’ was used to link the search terms. 
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Study Selection Criteria 
All articles were independently searched for by the author and assessed for eligibility 
using predefined criteria (Table 1).  Eligibility criteria were based on the PICOTSS format: (1) 
target population: term and post-term asphyxiated neonates, (2) interventions: adenosine 
antagonist (theophylline or aminophylline) for either prophylaxis or treatment, (3) comparison: 
placebo, (4) outcome: acute kidney injury as defined by use of measures of kidney function such 
as serum creatinine level, glomerular filtration rate, and urinary β2 microglobulin, and (5) study 
design: RCTs.   
 
Table 1:  PICOTSS Search Criteria Used for Study Selection 
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Data Extraction 
Data extraction was performed by a single reviewer using a standardized data collection 
form.  The following data were abstracted for all included studies: author, year, country, single-
center or multi-center status, definitions adopted, overall sample size, group sample sizes, level 
of randomization, study setting, study duration, inclusion and exclusion criteria, duration of 
follow-up, demographic data, the proportion of patient with the primary outcome, and measured 
drug level if available.  The primary outcome was the incidence of severe renal dysfunction.  
Secondary outcome measures were changes in serum creatinine, GFR, and urine β2-
microglobulin, if available.  Adverse reactions to treatment with theophylline or aminophylline 
were collected if they occurred within the first five days of life.  
 
Assessment of Trial Quality 
Assessment of randomized control trial quality was assessed by a single reviewer.  The 
methodological quality of the individual studies was assessed using a single method.  We 
assessed the quality of studies as good, fair, or poor, using pre-defined criteria developed by the 
United States Preventive Services Task Force (USPSTF) and adapted for this topic (Appendix A 
Table 2).34   
 
Data Synthesis and Analysis 
When multiple similar RCTs were available, quantitative synthesis was conducted with 
random-effects models using the inverse-variance weighted method (DerSimonian and Laird) to 
estimate pooled effects. Review Manager (RevMan) Version 5.3 (The Cochrane Collaboration, 
Copenhagen, Denmark) was used for all statistical analysis.  To analyze categorical outcomes, 
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the risk ratios (RR) were estimated along with their 95% confidence intervals (CIs).  Continuous 
outcomes were assessed using the weighted mean difference as well as the 95% CIs.  For each 
outcome of interest, effect estimates were pooled assuming a random-effect modeling approach.  
Statistical heterogeneity across studies was assessed using both I2 and Q statistics; p< 0.05 was 
defined to note statistical significance in the analysis of heterogeneity.   
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RESULTS  
The literature review results are shown in figure 1.  In the initial database searches, 89 
citations were identified; 78 were excluded as not relevant (primarily for wrong intervention, 
wrong study design or wrong population).  The full-texts of 15 potentially relevant citations were 
reviewed and 5 RCTs met full eligibility criteria; full-text exclusion reasons are outlined in 
figure 1.  
 
Figure 1: Article Flow Diagram for Theophylline/Aminophylline Intervention 
 
 
Study Characteristics 
Study characteristics are summarized in Table 2. All 5 included RCTs were conducted 
between 2000 and 2016, and all were conducted in non-US countries – Argentina, India, Egypt, 
and Iran.28,35-38  Included studies used similar eligibility criteria for asphyxiation, such as a first 
minute Apgar Score less than or equal to 3 or a five minute Apgar score greater than or equal to 
6, as well as the need for vigorous resuscitation using mask or endotracheal tube for positive 
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pressure ventilation.  Four studies also used a base deficit of 15 mEq/L in cord blood or arterial 
blood gas.36-38  Two mentioned the need for fetal distress.36,37  Only one study mentioned the 
presence of seizures as an inclusion criteria for asphyxiation.28  For defining acute kidney injury, 
all studies used a serum creatinine level of greater than or equal to 1.5 mg/dL for two 
consecutive days.28,35-38  Three of the studies also used the criteria of a 0.3 mg/kg/day increase in 
serum creatinine.36-38  All of the studies gave a single dose of IV theophylline to the intervention 
group within the first hour after birth28,35-38; however, three of the studies used a 5 mg/kg dose of 
theophylline28,35,38 while the other two used an 8 mg/kg dose of theophylline.36,37  Four out of 
five studies included a five day follow-up period28,35,37,38, while one of the studies included a five 
day follow up period as well as followed up at one year.36  All of the studies reported acute 
kidney injury as the primary outcome, while the secondary outcomes reported were serum 
creatinine (SCr), glomerular filtration rate (GFR), fluid balance, creatinine clearance, urinary 
sodium excretion, weight change, total urine output, and β2-microglobulin levels.  Finally, only 
one study out of five reported theophylline levels during their study.37 
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Table 2: Characteristics of Studies Included in Systematic Review and Meta-Analysis 
Study & Year Country
Number 
of Infants
Inclusion Criteria for Asphyxia
Inclusion Criteria 
for AKI 
THEO Dose
Timing of 
THEO 
Administrati
on
Follow-up
Primary 
Outcomes 
Reported 
Secondary 
Outcomes 
Reported 
THEO 
Level 
Reported
Raina, 2016 India 159
1) Apgar ˂ or = 3 in 1st minute or 
Apgar of up to 5 in the 5th minute                                    
2) positive pressure ventilation for 
more than 10 minutes                      
3) seizures                                                                               
4) severe hypotonia                                                     
5) Thomson score > 15  
Used Neonatal 
KDIGO 
Guidelines: a rise 
in SCr more than 
1.5 times the
lowest previous 
value
single dose 
of IV 
theophylline                             
(5 mg/kg, 
0.25 ml/kg)
Over a 5 
minute 
period within 
the first hour 
of birth
5 days
Acute 
Kidney 
Injury
Serum 
creatinine, 
GFR, fluid 
balance,  
creatinine 
clearance, 
urinary sodium 
excretion
No
Eslami, 2009 Iran 36
1) Apgar ˂ or = 3 in 1st minute, or 
Apgar of ˂ or = 6 in the 5th minute                                                  
2) base deficit higher than 15 
mEq/L in cord or arterial blood 
sample                                                
3)  need for severe resuscitation
An increase in 
SCr ≥ 0.3 mg/dL 
or an SCr > 1.5 
mg/dL for at least 
2 consecutive 
days after a fluid 
challenge
 slow single 5 
mg/kg IV 
dose of 
theophylline
Within first 5 
min after 
NICU 
admission, 
within 1 hour 
after birth
5 days
Acute 
Kidney 
Injury
Serum and 
urinary 
creatinine, 
GFR, urinary 
sodium 
excretion
No
Baht, 2006 India 70
1) History of fetal distress                     
2) Need for immediate neonatal 
ventilation with a bag and mask or 
through endotracheal intubation for 
> 2 minutes after delivery        3) A 
5-minute Apgar score of < or = 6                                               
4) Base deficit ≥ 15 mEq/L in cord 
blood or admission arterial blood 
or cord blood pH <7
 SCr >1.50 mg/dl 
for two 
consecutive days 
and rising SCr  
level (0.3 
mg/kg/day)
single dose 
of 
theophylline 
(8 mg/kg; 0.3 
mL/kg)
Within the 
first hour 
after birth
1 year
Acute 
Kidney 
Injury
Serum 
creatinine, 
urinary sodium 
excretion, fluid 
balance, 
weight 
changes, urine 
output
No
Bakr, 2005 Egypt 40
1) 5 min Apgar score of six or 
lower                                                
2)base deficit >15 mEq/l in cord 
blood or admission blood gas       
3) requirement of vigorous 
resuscitation (positive pressure 
ventilation and/or chest 
compression and/or use of 
adrenaline)
SCr >1.50 mg/dl 
for two 
consecutive days
single dose 
of 5 mg/kg IV 
theophylline, 
slow push 
over 5 
minutes
Within the 
first hour 
after birth
5 days
Acute 
Kidney 
Injury
Serum 
creatinine, fluid 
balance, 
creatinine 
clearance, 
GFR, β2-
microglobulin
No
Jenik, 2000 Argentina 51
1) history of fetal distress (late 
decelerations decreased heart 
rate variability, or bradycardia 
(<100 bpm with or without 
meconium stained amniotic fluid)                                                   
2) 5-minute Apgar score of  6 or 
lower                                                      
3) base deficit equal to or greater 
than 15 mEq/L in cord blood or 
admission arterial blood sample                                  
4) requirement of immediate 
neonatal  ventilation with mask or 
tracheal tube for > 2 minutes after 
delivery
SCr > 1.50 mg/dL 
for at least 2 
consecutive days 
after a fluid 
challenge 
consisting of a 
total of 20 mL/kg 
of normal saline, 
or rising levels of 
serum creatinine 
(0.3 mg/dL/day)
single dose 
of IV 
theophylline 
(8 mg/kg; 1.6 
mg/kg)
Over a 5 
minute 
period within 
the first hour 
after birth
5 days
Acute 
Kidney 
Injury
Serum 
creatinine, fluid 
balance, 
creatinine 
clearance, 
GFR, urinary 
sodium 
excretion, 
urinary β2-
microglobulin
Yes
 
Note: To meet the criteria for asphyxiation, infants must meet at least two of the inclusion 
criteria.  To meet the criteria for AKI, infants must meet the individual criteria listed above. 
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Quality of Included Studies 
Quality assessment for all included RCTs is detailed in Appendix B Table 1.  All studies 
were rated as good quality.  One methodological flaw of the studies was small sample sizes; even 
the most recent study by Raina, et al., which included 159 infants, was underpowered as they 
were not able to recruit enough patients into the study.   Selection bias and measurement bias risk 
was found to be low in all studies.  Only the Jenik, et al. study was a multicenter trial, while the 
rest took place at single centers. The attrition rates were found to be low as all of the studies 
reported complete follow-up at five days with all of the infants included in the trial.  However, 
only one study continued to follow the infants further, every two weeks after birth to two months 
and then monthly up to 1 year of age.36  All studies used similar and appropriate strategies for 
statistical analysis.  For a complete quality evaluation for each individual RCT included in the 
analysis, see Appendix B, Tables 2-6.   
 
Results 
Incidence of Acute Kidney Injury  
Five randomized control trials were included in the meta-analysis.  Data was used for a 
total of 356 infants, with 179 infants receiving treatment with theophylline and 177 receiving the 
control of either normal saline or a 5-10% dextrose solution.  All trials included acute renal 
failure as their primary outcome and evidence of risk reduction (RR) for the use of theophylline 
in severely asphyxiated term infants.  The overall pooled RR for developing acute kidney injury 
using a random-effects model was 0.36 (95% CI, 0.25 to 0.5; p <0.00001) (Figure 2).  There was 
no evidence of statistical heterogeneity between studies (I2 = 0%, χ2= 0.79, P=0.94).   
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Figure 2: Forest plot of relative risks and 95% confidence intervals (CIs) for acute kidney 
injury in asphyxiated neonates who received theophylline as compared with placebo from 
five RCTs. 
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Differences in Serum Creatinine and Glomerular Filtration Rate 
All five studies included in the meta-analysis examined serum creatinine (SCr) levels and 
glomerular filtration rates for severely asphyxiated term infants treated with either theophylline 
or the control.  Table 3 shows a summary of the data reported in each study over five days.  For 
the analysis, data from days 1, 3, and 5 were included as these values for SCr and GFR were 
given in all five studies. 
Figure 3 shows a forest plot of the differences in SCr levels and 95% CIs between the 
theophylline and control groups from the five RCTs.  For SCr on day 1, there was evidence of 
high statistical heterogeneity across studies (I2=90%, χ2=41.97, p < 0.0001).  Moderate 
heterogeneity on day 3 was found to be not statistically significant (I2=37%, χ2=6.38, p=0.17).  
On day 5, high statistical heterogeneity was found across studies for differences in SCr levels 
(I2=75%, χ2= 15.92, p=0.003).  Using a random effects model, the pooled estimate of SCr on day 
1 was found to be not statistically significant at -0.19 (95% CI, -0.44 to 0.07; p=0.16).  However, 
SCr on days 3 and 5 favored the theophylline group and was statistically significant.  On day 3, 
the pooled estimate of SCr was -0.56 (95% CI, -0.72 to -0.40; p<0.0001).  On day 5, the pooled 
estimate of SCr was -0.35 (95% CI, -0.53 to -0.16; p=0.002).   
Figure 4 shows a forest plot of the differences in GFR levels and 95% CIs between the 
theophylline and control groups from the five RCTs.  For GFR, the tests for heterogeneity were 
not significant across studies on day 1 (I2=47%, χ2=5.65, p=0.13), day 3 (I2=0%, χ2=0.09, 
p=0.99), and day 5 (I2=47%, χ2=5.63, p=0.13).  Using a random effects model, the pooled 
estimate of GFR on day 1 was found to be not statistically significant at 1.17 (95% CI, -2.82, 
5.16; p=0.56).  However, statistically significant improvements in GFR were found on days 3 
and 5.  For day 3, the pooled estimate of GFR was found to be 14.30 (95% CI, 11.73 to 16.87; 
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p<0.00001).  On day 5, the pooled estimate of GFR was estimated to be 10.5 (95% CI, 5.81 to 
14.29; p<0.00001).  
 
Secondary Results Reported by Included Trials 
For our analysis, we did not include non-clinically significant outcomes such as fluid 
balance, creatinine clearance, urinary sodium excretion, weight change, total urine output, and 
β2-microglobulin levels.  Urinary creatinine levels and urinary sodium levels are not a reliable 
measure for acute kidney injury.  Similarly, fluid balance, weight gain, and total urine output are 
subjective measures that could be affected by clinical practice and as such were not included in 
the analysis.  Statistical tests were performed for β2-microglobulin examining heterogeneity 
between studies and pooled estimates of the differences between treatment with theophylline and 
the control.  However, there were only two studies that included data for β2-microglobulin. A 
forest plot of the results are located in the appendix.   
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Table 3: Serum Creatinine and Glomerular Filtration Rate as Reported in the RCTs in the 
study. 
Study & Year
Outcome 
Measure
Day 1 Day 2 Day 3 Day 4 Day 5
THEO Control THEO Control THEO Control THEO Control THEO Control
Raina, 2016
Serum 
creatinine 
(mg/dL)
1.22 ± 0.68 1.28 ± 0.51 N/A N/A 0.83 ± 0.35 1.47 ± 0.61 N/A N/A 0.82 ± 0.52 1.09 ± 0.63 
Eslami, 2009 0.92 ± 0.22 0.86 ± 0.20 N/A N/A 0.63 ± 0.22 1.06 ± 0.47 N/A N/A 0.56 ± 0.14 0.73 ± 0.14 
Baht, 2006 1.18 ±  0.69 1.5 ± 0.68 0.92 ± 0.65 1.56 ± 0.92 0.95 ±0.50 1.59 ± 0.92 0.94 ± 0.45 1.62 ± 1.03 0.82 ± 0.47 1.57 ± 0.90
Bakr, 2005 1.23 ± 0.19 1.20 ± 0.19 1.22 ± 0.24 1.41 ± 0.29 1.24 ± 0.39 1.57 ± 0.61 1.31 ± 0.38 1.59 ± 0.44 1.29 ± 0.27 1.47 ± 0.41 
Jenik, 2000 1.0 ± 0.3 1.05 ± 0.4 0.97 ± 0.17 1.51 ± 0.41 1.02 ± 0.69 1.94 ± 1.1 0.89 ± 0.7 1.59 ± 0.7 0.71 ± 0.2 1.36 ± 0.9 
Raina, 2016
GFR 
(ml/min)
28.21 ± 22.27 21.37 ± 13.55 N/A N/A 32.16 ± 16.34 17.73 ± 7.92 N/A N/A 41.47 ± 27.24 32.7 ± 26.67
Eslami, 2009 25.4 ± 7.3 28.2 ± 12.8 N/A N/A 42.4 ± 19.1 27.5 ±  10.7 N/A N/A 42.3 ± 12.5 37.5 ± 6.5       
Baht, 2006 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Bakr, 2005 21.10 ± 9.3 22.11 ± 8.7 25.13 ± 9.1 15.32 ± 7.1 26.02 ± 10.8 12.39 ± 4.6 27.48 ± 10.2 14.35 ± 6.8 29.31 ± 9.9 19.10 ± 8.7
Jenik, 2000 23.17 ± 10.3 22.07 ± 9 24.01 ± 8.6 14.9 ± 6.8 25.94 ±11.2 11.36 ± 5.1 27.29 ± 9.1 32.41 ± 7.4 32.41 ± 7.4 18.0 ± 9.8
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Figure 3: Forest plot of relative risks and 95% confidence intervals (CIs) of differences in 
serum creatinine levels between theophylline and control groups from five RCTs on day 1, 
day 3, and day 5.  
 
Day 1: 
 
Day 3: 
 
Day 5: 
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Figure 4: Forest plot of relative risks and 95% confidence intervals (CIs) of differences in 
glomerular filtration levels between theophylline and control groups from five RCTs on 
day 1, day 3, and day 5. 
 
Day 1: 
 
Day 3: 
 
Day 5: 
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DISCUSSION  
The goal of this systematic review and meta-analysis was to determine whether 
theophylline could prevent or ameliorate acute kidney injury in term neonates with perinatal 
asphyxia.  Ultimately five RCTs were included in the review and meta-analysis.  Our results 
indicate that prophylactic theophylline given within the first hour after birth is associated with a 
reduction in the incidence of acute kidney injury compared with placebo (RR 0.36 (95% CI, 0.25 
to 0.5; p <0.00001)).  We also found that markers of renal injury such as serum creatinine and 
glomerular filtration rates also improved with the administration of theophylline.   
Although results for reduction in incidence of AKI were consistent across trials, there 
were some differences across studies in the magnitude of effect.  For example, dosing of 
theophylline was one issue that may have affected the results of the meta-analysis.  Three of the 
five included studies used a 5 mg/dL single IV dose based on previous studies of apnea of 
prematurity28,35,38, while two of the studies used a single 8 mg/dL IV dose36,37 based on a 
different study of apnea of prematurity.39  While our results show a low I2 indicating that the 
amount of heterogeneity between studies was low, the magnitude of effect for the change in 
creatinine appeared to be greater in the two studies that used the 8 mg/kg theophylline dose 
compared with the 5 mg/kg dose suggesting that the higher dose may confer more therapeutic 
benefits.  Currently, there are no studies that have directly compared different dosing of 
theophylline in neonates for acute kidney injury in infants with perinatal asphyxiation.  Future 
studies must be conducted to address the optimal dosing of theophylline in these patients as well 
as what numerical difference in these biological markers indicates actual observable clinical 
benefits to these patients. 
In the literature on prophylactic theophylline for prevention or reduction of acute kidney 
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injury in asphyxiated term neonates, very little is reported about the toxicity and possible harms 
of theophylline.  In all of the past studies, only a single dose of theophylline was given 
depending on the specific study (either 5 mg/kg or 8 mg/kg), thus limiting any direct 
comparisons that could be made about its toxicity.  While treatment with theophylline confers 
such benefits as a reduction of acute kidney injury, commonly associated harms of theophylline 
include seizures and CNS excitability.24  Notably, theophylline has a narrow therapeutic index 
making the optimal selection of the dose critical.30  In the five RCTs used in the study, harms are 
mentioned such as death from the causes of multi-organ failure, persistent pulmonary 
hypertension of the newborn secondary to meconium aspiration, and severe encephalopathy.  
Other harms reported in the study were seizures, cerebral hemorrhage, hematuria, proteinuria, 
and requirement of a blood transfusion.  While all five studies quantified the incidence of 
different types of harms during their studies, no RCTs directly attributed any harms to 
theophylline use.  It cannot be concluded that these harms are a result of theophylline treatment 
as no analysis was performed to reduce confounding factors.  Perinatal asphyxiation is a serious 
and complicated condition.  Variation with individual clinical regimens as well as center to 
center variation in treatment of asphyxiation and its common comorbidities may be affecting the 
negative outcomes observed by the studies.   
 All five studies were completed in nations outside of the US – one in Argentina, one in 
Egypt, one in Iran, and two in India.  Researchers from these countries were interested in finding 
an effective treatment for ameliorating acute kidney injury in asphyxiated neonates as they do 
not have the resources for hypothermic cooling.  Induced whole-body infant cooling (also called 
induced hypothermia) is the mainstay of treatment for HIE in developed countries.  This method 
is thought to work by eliminating the second round of hypoxic-ischemic damage to the brain that 
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occurs approximately six hours after an asphyxiation event.  In 2013, a Cochrane review was 
conducted to determine the effect of therapeutic hypothermia with standard care on mortality, 
long-term neurodevelopmental outcomes, and side effect profile.40  Their study was based on 11 
randomized control trials and included 1505 term infants with moderate to severe 
encephalopathy.  After analysis, the investigators found that therapeutic hypothermia resulted in 
statistically significant and clinically important reduction in mortality or major 
neurodevelopmental disability at 18 months of age, but had some adverse side effects of sinus 
bradycardia and thrombocytopenia.40  However, little attention has been focused on whether or 
not induced hypothermia for HIE also improves outcomes related to AKI.  Notably, none of the 
five RCTs used in our systematic review and meta-analysis directly compared theophylline 
versus hypothermic cooling for preventing or reducing acute kidney injury in this population.  
Also, none of these studies concurrently looked at the use of a prophylactic dose of theophylline 
with hypothermic cooling to examine whether using the treatments together could have additive 
beneficial effects.  Future research both directly comparing theophylline and hypothermic 
cooling as well as research examining use of theophylline and hypothermic cooling is warranted.  
 
Strengths and Limitations  
Of the body of literature that exists on the use of prophylactic theophylline for acute 
kidney injury in asphyxiated neonates, this systematic review and meta-analysis is the most 
comprehensive to date.  While there were only five RCTs included in the analysis, a strength of 
this review is that our analysis included analysis of the SCr level of 356 infants and the GFR of 
286 infants, which are the largest numbers to be included in a meta-analysis of this nature. Also, 
due to lack of data, we could not conduct a subgroup analysis to examine factors that could be 
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affected heterogeneity between the studies.  In terms of methods, this review used a 
comprehensive literature search and quality assessment of all included trials; one limitation (due 
to time and resources) was that a single reviewer conducted the literature review and data 
abstraction.  
 
Clinical Implications 
This review and meta-analysis provides evidence that the prophylactic use of 
theophylline significantly decreases the incidence of acute kidney injury and causes significant 
improvement in other secondary measures of renal injury such as SCr and GFR over a five day 
period in term asphyxiated neonates.  As these studies were limited to the narrow study 
population severely asphyxiated neonates ≥ 37 weeks, the efficacy of theophylline for the 
prevention of acute kidney injury in younger, older, or less sick populations cannot be 
determined at this time.  While promising for potential use in future clinical practice, further 
studies should assess the optimal dose of theophylline to incur maximum benefits and minimal 
harms.  Although some harms were mentioned in the study, small sample sizes and the lack of 
further analysis to investigate possible confounders of these harms need to be more closely 
evaluated.   
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CONCLUSIONS  
The goal of this systematic review and meta-analysis was to determine whether 
theophylline could prevent or ameliorate acute kidney injury in term neonates with perinatal 
asphyxia.  These results indicate that prophylactic theophylline given within the first hour after 
birth is associated with a reduction in the incidence of acute kidney injury.  We also found that 
markers of renal injury such as serum creatinine and glomerular filtration rates also improved 
with the administration of theophylline.  This study provides the largest amount of evidence to 
date in favor of using prophylactic theophylline to prevent acute kidney injury in neonates with 
perinatal asphyxia.  The conclusions of this review are especially important as the use of 
theophylline may drastically improve renal outcomes in low resource countries without access to 
induced hypothermia, the current standard of care for perinatal asphyxiation in well-resourced 
countries.  As there have been no studies directly comparing treatment with theophylline to 
induced hypothermia for acute kidney injury in asphyxiated neonates, more research must be 
done in the future to see if theophylline could be used alone or concomitantly with induced 
hypothermia to improve acute kidney injury in well-resourced NICUs.  Lastly, more studies must 
be done to examine the optimal dosing of theophylline treatment in the neonatal population as 
well as potential adverse effects.   
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APPENDIX A: Methods 
Appendix A Table 1. PubMed and EMBASE Search Strategy 
Database PubMed 
Search Strategy #1 AND #2 AND #3 AND #4 
#1 
("theophylline"[MeSH Terms] OR "theophylline"[All Fields]) AND 
("infant"[MeSH Terms] OR "infant"[All Fields]) AND 
("kidney"[MeSH Terms] OR "kidney"[All Fields]) 
#2 
("theophylline"[MeSH Terms] OR "theophylline"[All Fields]) AND 
("infant, newborn"[MeSH Terms] OR ("infant"[All Fields] AND 
"newborn"[All Fields]) OR "newborn infant"[All Fields] OR 
"newborn"[All Fields]) AND ("kidney"[MeSH Terms] OR 
"kidney"[All Fields]) 
#3 
("theophylline"[MeSH Terms] OR "theophylline"[All Fields]) AND 
("infant, newborn"[MeSH Terms] OR ("infant"[All Fields] AND 
"newborn"[All Fields]) OR "newborn infant"[All Fields] OR 
"newborn"[All Fields]) AND ("acute kidney injury"[MeSH Terms] 
OR ("acute"[All Fields] AND "kidney"[All Fields] AND "injury"[All 
Fields]) OR "acute kidney injury"[All Fields]) 
#4 
HIE[All Fields] AND ("infant, newborn"[MeSH Terms] OR 
("infant"[All Fields] AND "newborn"[All Fields]) OR "newborn 
infant"[All Fields] OR "newborn"[All Fields]) AND ("acute kidney 
injury"[MeSH Terms] OR ("acute"[All Fields] AND "kidney"[All 
Fields] AND "injury"[All Fields]) OR "acute kidney injury"[All 
Fields]) 
  
Database  EMBASE 
Search Strategy #1 AND #2 AND #3 AND #4 
#1 theophylline AND infant AND kidney 
#2 
(theophylline/exp OR theophylline) AND (infant/exp OR infant) 
AND acute AND (kidney/exp OR kidney) AND (injury/exp OR 
injury) 
#3 theophylline AND newborn AND acute AND kidney AND failure 
#4 hie AND infant AND acute AND kidney AND injury 
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Appendix A Table 2. RCT Quality Appraisal Tool 
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APPENDIX B: Results 
APPENDIX B Table 1. Summary of the Methodological Quality of Included RCTs 
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APPENDIX B Table 2. Critical Appraisal of Raina, 2016 
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APPENDIX B Table 3. Critical Appraisal of Eslami, 2009 
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APPENDIX B Table 4. Critical Appraisal of Baht, 2006 
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APPENDIX B Table 5. Critical Appraisal of Bakr, 2005 
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APPENDIX B Table 6. Critical Appraisal of Jenik, 2000 
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APPENDIX B: Figure 1 – Forest plot of differences in urinary β2-microglobulin levels and 
95% confidence intervals (CIs) between theophylline and control groups on Day 1.   
 
Day 1: 
 
 
Although there were only two studies, we were interested in examining the differences in urinary 
β2-microglobulin levels and 95% confidence intervals (CIs) between theophylline and control 
groups.  Unfortunately due to lack of data, we were only able to analyze differences in the β2-
microglobulin levels on day 1 across the two studies.  The heterogeneity across studies was not 
statistically significant (I2=35%, χ2=1.53, p=0.22).  Using a random effects model, the pooled 
estimate of β2-microglobulin levels on day 1 was found to be -4.80 (95% CI, -7.44 to -2.16; 
p=0.0004) favoring asphyxiated infants treated with theophylline.  Due to the small number of 
studies and study participants, further research needs to be performed focused on urinary β2-
microglobulin levels.   
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